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When the seventh annual Frontiers in Health Policy Research meeting
was held in Washington, D.C., in the summer of 2003, the climate for
health care reform had decidedly changed from only a few years ear-
lier. The projected federal budget surplus had been replaced by a
budget deficit, with red ink projected to flow for the foreseeable future.
Solutions to rising health expenditures seemed elusive as commercial
health insurance premiums continued to rise at double-digit rates for
the third consecutive year. The only major Medicare reform under seri-
ous consideration in Congress was a much-desired expansion of cov-
erage for prescription drugs; plans to cope with rising Medicare
expenditures were, for the time being, a lower priority. Along with
rising health expenditures, the number of urinsured increased. The
economic challenges were intense.
The papers in this volume represent some of the best thinking
among leading economists about these contemporary health policy
challenges. The authors, affiliated with the National Bureau of
Economic Research, aim to foster a dialogue with the policy commu-
nity. The papers were presented at a meeting attended by both aca-
demic researchers and health care experts within government and
private organizations, and they are written for anyone concerned about
the U.S. health care system and its future.
To many observers, pharmaceuticals epitomize both the successes
and failures of the U.S. health care system. The rapid pace of irmova-
tion has made it possible to treat a range of conditionssuch as high
blood cholesterol, anemia, depression, and some cancersmore effec-
tively than ever before. The benefits of innovation are genuine and sub-
stantial. But the medications that have been introduced for these
conditions are often expensive. In recent years, pharmaceuticals have
attracted a good deal of policy attention because they have comprisedxii Introduction
the leading component of health expenditure growth. Reports that resi-
dents of Canada and the wealthy nations of Europe pay less for the
same drugs have fueled the debate about the fairness and sustainability
of pharmaceutical markets in the United States.
Outside the United States, particularly in western Europe, reference
pricing has become a popular approach to the provision of pharma-
ceutical benefits. The logic of reference pricing is similar to the use of
tiered copayments for drugs in private health plans in the United
States. A group of closely substitutable drugs is defined, and the payer
(a health authority or health plan) usually adopts the price of the least
expensive drug in the group as the reference price. The patient is free
to choose any of the drugs in the class but must pay the difference
between the drug's price and the reference price. Unlike direct price
controls, this approach enables markets to function, with support for
higher prices dependent on the demand for perceived superiority.
In both a theoretical analysis and an empirical examination of the
effects of reference pricing in three countries, Patricia M. Danzon and
Jonathan D. Ketcham show that reference pricing approaches may not
simply lower pricesthey may have effects on the rate of introduction
of new drugs, on their success in the market, and therefore on the
returns to innovation. Danzon and Ketcham analyze reference pricing
in Germany, the Netherlands, and New Zealand. They show that, in
countries with the most aggressive reference pricing, the availability of
new compounds is significantly delayed. Although their analysis does
not address the full welfare consequences of reference pricing and
alternative approaches to providing a pharmaceutical benefit, they
draw important lessons for the design of a Medicare drug benefit.
Most of those in favor of a Medicare drug benefit share the assump-
tion that any such benefit, at least initially, should be a stand-alone pro-
gram; that is, it should be complementary to traditional Medicare, not
an integrated benefit within Medicare. In this respect, it contrasts with
nearly all other health insurance, which includes medication coverage
as one of the many categories of covered products and services. The
voluntary nature of the Medicare drug benefit and its pricing can make
participation unattractive for Medicare beneficiaries who don't expect
to spend much money for prescription drugs or otherwise would gain
little by participating in the program, giving rise to adverse selection.
According to Mark V. Pauly and Yuhui Zeng, this kind of adverse
selection could be a threat to any stand-alone Medicare drug benefit.
Examining multiyear data on a large group of workers covered byhitroduction xiii
employment-based health insurance, they find that high-cost users of
prescription drugs tend to have high expenditures from one year to the
next, so that drug expenditures are more predictable than other health
expenditures. This predictability of spending makes a drug benefit par-
ticularly vulnerable to adverse selection. Pauly and Zeng show that
even large subsidies might fail to keep a voluntary Medicare drugben-
efit from being subject to a death spiral as the program becomes attrac-
tive to an ever-shrinking pool of beneficiaries with ever-increasing
average drug expenditures. They also show, however, that bundling
the drug benefit with other coverage can mitigate adverse selection.
At the foundation of nearly every Medicare reform proposal is a set
of assumptions about the program's future liabilities. Some aspects of
these projections, such as the number of Medicare beneficiaries in
different age categories, are not controversial, while others, especially
per-beneficiary expenditures, are more speculative. Expenditures per
beneficiary depend on reimbursement rates, rates of utilization of cov-
ered services, and the types and costs of forms of care that are intro-
duced in the coming years. Health status is decisive here; healthier
Medicare beneficiaries are expected to use less, and less expensive,
health services. High-cost users of Medicare-covered services, espe-
cially those who are approaching the end of their lives and those with
disabilities, use more.
Recent evidence suggests that rates of disability are declining among
the elderly: good news both because it is a harbinger of better quality
of life for the elderly and because it suggests that Medicare expenditure
growth may well be lower than many had expected. But will the trend
continue for future cohorts of the elderly? Jayanta Bhattacharya and
colleagues address this question by combining data on current
Medicare beneficiaries with data on younger cohorts and projecting
future Medicare expenditures based in part on their current health
characteristics. They show that declining disability will suppress per-
capita Medicare expenditure growth for the near term (less than
twenty years), but in subsequent years the rising disability rates among
current cohorts of the young will lead to an increase in per-capita
Medicare expenditures.
Determining the impact of financial incentives on the quality of care
has been a vexing issue for economists and policy makers alike. In their
paper, William H. Crown and colleagues develop a novel way to inves-
tigate this issue. They examine the effect of out-of-pocket payments for
asthma medications on the relative use of controller and relieverxiv Introduction
medications. Greater use of controllers is a sign of better quality care,
and this information allows the authors to learn about the impact of
cost sharing on quality Using data from many large firms, Crown and
co-authors find that cost sharing has little impact on the use of con-
troller medications relative to reliever medications. This finding sug-
gests that increases in cost sharing may not be particularly harmful,
although it leaves open the question of which policies might be more
effective in improving the quality of care.
Beginning in the 1990s, health insurance markets began to change
dramatically as several health plans converted from nonprofit to for-
profit status, often as a prelude to mergers. This phenomenon was part
of the growing consolidation among health plans nationwide.
Although considerable public attention has been paid to this phenom-
enon, and concern about it has increased among employers, hospitals,
other health care providers, and the general public, the welfare conse-
quences of such conversions have not been studied thoroughly. Nancy
Dean Beaulieu examines a specific for-profit conversion, that of the
CareFirst corporation in Maryland, the District of Columbia, and
Delaware. Beaulieu reviews the reasons for considering for-profit
conversions, the multiple considerations in determining whethera
for-profit conversion might be in the public interest, the effects of
conversion on the quality of care, and the role of market concentration.
She also examines evidence concerning one of the key arguments
supporting conversionthat the greater size made possible by the
improved access to capital in a conversion would help plans to achieve
economies of scale that would otherwise be absent. In addressing
these issues, her paper also supplies an agenda for future research on
for-profit conversions.
Although the papers included in this volume do not offer policy rec-
ommendations, each of them highlights important research findings
that bear on current policy initiatives. Each paper is likely to remain
relevant to health policy controversies in the years to come.
The conference at which these papers were presented was the work
of many people. We are particularly grateful to Donna Mattos and Lita
Kimble for arranging the meeting. Funding for the Frontiers in Health
Policy Research conference comes from the National Bureau of
Economic Research (NBER); we are grateful for their support.
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